The ASCP Annual Meeting is the premiere meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Susan Kornstein and Mark Rapaport with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2022 Steering Committee. A Program Committee under the leadership of Drs. Erika Saunders and Lee Cohen are responsible for the review of all program submissions.